Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Generic Priorities: McClellan Lays Out Ambitious Agenda At GPhA

This article was originally published in The Tan Sheet

Executive Summary

FDA is developing a process to flag NDAs that may pose difficulties for future generic development, Commissioner Mark McClellan, MD/PhD, said at the Generic Pharmaceutical Association annual meeting in Rio Grande, Puerto Rico Jan. 29
Advertisement

Related Content

FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
FDA “Strategic Plan” Team Takes Shape: McClellan Names Senior Advisors
FDA “Strategic Plan” Team Takes Shape: McClellan Names Senior Advisors
FDA “Strategic Plan” Team Takes Shape: McClellan Names Senior Advisors
Waxman’s Generic Reform: No 30-Month Stay, Early Declaratory Judgements
FDA Generics Review Staff To Increase 25% In President’s Budget Request
FDA Generics Review Staff To Increase 25% In President’s Budget Request
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims

Topics

Advertisement
UsernamePublicRestriction

Register

PS095082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel